Nearly 7 million Americans are living with Alzheimer’s disease, a number the Alzheimer’s Association projects will reach almost 13 million by 2050. Despite recent drug approvals targeting amyloid plaques, no treatment has been shown to stop or reverse the disease. The Salk Institute for Biological Studies in La Jolla, California, is now wagering that the next generation of prevention strategies will come not from studying the brain in isolation but from understanding how the heart, immune system, and everyday habits shape it over a lifetime.
In its official 2026 declaration, Salk designated this year its “Year of Brain Health,” building on an Alzheimer’s-focused research agenda launched in 2025. The campaign is backed by nearly $40 million in dedicated grant funding and organized around a central premise: that brain health is a product of cardiovascular circulation, immune signaling, metabolism, physical exercise, sleep, and mental well-being, all working together.
Two major grants anchor the research
The initiative’s scientific backbone comes from two separately funded programs already underway at the institute.
The first is the Neuroimmunology Initiative, supported by a $20 million, four-year gift from the NOMIS Foundation. It is organized into two research tracks: “Body to Brain,” which investigates how immune signals originating outside the central nervous system influence neurological function, and “Brain to Body,” which examines how brain states alter immune responses throughout the rest of the body. The dual structure reflects a growing body of published research linking chronic neuroinflammation to Alzheimer’s progression, including work suggesting that the immune system may actively accelerate cognitive decline rather than simply responding to it.
The second is a $19.2 million, eight-year award from the American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment. Led by neuroscientist Rusty Gage, the program targets the intersection of cardiovascular aging and brain degeneration. The AHA’s decision to fund Alzheimer’s-related research at this scale is itself notable: it reflects the cardiology establishment’s recognition that vascular health and dementia risk are deeply intertwined, a connection supported by large epidemiological studies showing that midlife hypertension, poor circulation, and cardiovascular disease all raise the odds of later cognitive impairment.
Why the focus on blood flow and immunity
For decades, Alzheimer’s research concentrated heavily on amyloid-beta plaques and tau tangles, the hallmark protein deposits found in the brains of patients with the disease. That focus produced the recently approved drugs lecanemab and donanemab, which reduce amyloid but have shown only modest effects on slowing cognitive decline. Multiple research groups have published findings indicating that amyloid removal alone is insufficient, and several prominent Alzheimer’s researchers, including those involved in the Lancet Commission on dementia prevention, have argued in peer-reviewed work that the field needs to address upstream factors, such as vascular dysfunction and chronic inflammation, that make the brain vulnerable in the first place.
Salk’s initiative is positioned squarely in that upstream space. In a podcast conversation archived as part of the Year of Brain Health, Gage described the brain’s extraordinary energy demands: it consumes roughly 20 percent of the body’s oxygen despite accounting for only about 2 percent of its weight. When cardiovascular fitness declines with age, the brain is among the first organs to feel the effects. Exercise, Gage explained, improves circulation and delivers the oxygen and nutrients that sustain neuronal function during aging. Gage’s comments are drawn from that institutional podcast; no independent interview with him has been published in the sources reviewed here.
Salk President Gerald Joyce, speaking in the same recorded discussion, framed the initiative as a research strategy rather than a public awareness campaign alone. His comments positioned the Year of Brain Health as an institutional commitment to investigating the biological mechanisms through which the body’s systems protect or fail the aging brain.
Public engagement and community outreach
The institute held a public event on February 25, 2026, titled “Celebrate Salk’s Year of Brain Health: An Evening with Experts,” at its La Jolla campus. According to the official event listing, the gathering ran from 5:00 to 7:00 p.m. and covered the initiative’s core themes: cardiovascular fitness, immune and metabolic health, exercise, mental well-being, and sleep. The event was designed to translate the institute’s research priorities into accessible discussions for the broader community. No independent media coverage, public transcript, or recording has been released confirming what specific findings, if any, were shared at the event.
What the initiative has not yet shown
For all its ambition and funding, the Year of Brain Health is still in its early stages, and several important details remain undisclosed.
Neither the Neuroimmunology Initiative nor the AHA-Allen program has published primary research protocols, preliminary data, or descriptions of specific molecular targets, patient cohorts, or biomarker strategies. Both programs are described at the level of institutional announcements, not peer-reviewed science. That is not unusual for initiatives of this scale and timeline, but it means the specific experimental approaches remain opaque.
There is also no public information about how the two funded programs coordinate with each other. The Neuroimmunology Initiative focuses on immune-brain communication; the AHA-Allen award centers on cardiovascular-brain connections. Whether Salk researchers are actively integrating data across these tracks, sharing infrastructure like imaging cores or bioinformatics pipelines, or running them as parallel efforts with separate governance has not been disclosed.
The initiative’s emphasis on lifestyle factors such as exercise, sleep, and mental well-being raises another open question. The public messaging highlights these as pillars of brain resilience, but the funding announcements focus on mechanistic biology: immune pathways, vascular aging, and cellular changes. Whether Salk plans to conduct intervention studies that directly test lifestyle modifications in human participants, or whether those themes will primarily inform hypotheses about underlying molecular pathways, remains unclear.
The funding timelines themselves set expectations. The NOMIS Foundation’s four-year window and the AHA-Allen award’s eight-year span suggest that meaningful translational results are years away. No specific milestones, such as target dates for first publications or planned clinical collaborations, have been announced. Readers should expect foundational science from this work, not near-term therapies.
No independent expert commentary on the Year of Brain Health initiative has appeared in the sources reviewed for this article. All scientific claims and framing originate from Salk’s own materials. Independent evaluation from researchers outside the institute will be an important factor in assessing the initiative’s significance as it matures.
Where this fits in the broader Alzheimer’s landscape
Salk’s integrative approach is not happening in a vacuum. The National Institute on Aging funds multiple large-scale studies examining how vascular risk factors, inflammation, and lifestyle interact with Alzheimer’s pathology. International efforts like the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) have already demonstrated that multi-domain lifestyle interventions, combining diet, exercise, cognitive training, and vascular risk management, can improve cognitive outcomes in at-risk older adults. Salk’s contribution, if its mechanistic research delivers, could help explain why those interventions work at the biological level and identify new molecular targets for prevention.
All of the core claims about the Year of Brain Health rest on institutional sources published directly by the Salk Institute: the initiative’s declaration page, the public event listing, the podcast transcript, and two funding announcements. The grant figures of $20 million and $19.2 million are documented in formal press releases, and the AHA-Allen award carries the additional credibility of a major cardiovascular organization with its own vetting processes for large research investments. Broader claims about the potential to “prevent” Alzheimer’s through integrated cardiovascular and immune strategies should be understood as scientific hypotheses guiding the research, not established outcomes.
Tracking the initiative’s progress through mid-2026 and beyond
The Year of Brain Health represents a significant institutional bet: that understanding how the heart, immune system, metabolism, and daily behaviors shape the aging brain will open new routes to delay or prevent dementia. The funding is real, the scientific rationale aligns with where the field is moving, and the researchers involved have strong track records. But the distance between a well-funded research agenda and a proven prevention strategy is long. The outputs that will determine whether this initiative delivers on its promise are still ahead: published study designs, early experimental findings, peer-reviewed papers, independent expert evaluation, and, ultimately, evidence that these approaches make a measurable difference for the millions of people at risk of Alzheimer’s disease. Those are the markers worth tracking in the months and years to come.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
